Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer Journal Article


Authors: Dagogo-Jack, I.; Shaw, A. T.; Riely, G. J.
Article Title: Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer
Abstract: In the 9 years since the initial discovery of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC), there has been tremendous progress, culminating in an ever-expanding repertoire of agents that have activity in this disease. This review article provides an overview of currently approved ALK inhibitors, other ALK inhibitors in development, and commonly described mechanisms of resistance to ALK inhibitors. We also discuss emerging controversies in treatment of patients with ALK-positive lung cancer, including the choice of first-line ALK inhibitor and the role of tyrosine kinase inhibitors in the treatment of central nervous system metastases. © 2017 American Society for Clinical Pharmacology and Therapeutics
Keywords: drug approval; cancer patient; lung cancer; cancer therapy; cancer resistance; protein tyrosine kinase inhibitor; gene rearrangement; heat shock protein 90 inhibitor; anaplastic lymphoma kinase; central nervous system metastasis; clinical trial (topic); crizotinib; cancer prognosis; human; priority journal; article; ceritinib; alectinib; anaplastic lymphoma kinase inhibitor; brigatinib; entrectinib; lorlatinib; ensartinib; anaplastic lymphoma kinase positive lung cancer
Journal Title: Clinical Pharmacology & Therapeutics
Volume: 101
Issue: 5
ISSN: 0009-9236
Publisher: Nature Publishing Group  
Date Published: 2017-05-01
Start Page: 625
End Page: 633
Language: English
DOI: 10.1002/cpt.653
PUBMED: 28182271
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 2 June 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Gregory J Riely
    501 Riely